Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study

Scand J Gastroenterol. 2012 Oct;47(10):1234-41. doi: 10.3109/00365521.2012.711855. Epub 2012 Aug 8.

Abstract

Background and aims: A prospective cross-sectional study was designed to test if total levels of TIMP-1 in saliva and plasma correlated with the diagnosis of colorectal cancer (CRC) in a population with symptoms consistent with this disease.

Materials and methods: Stimulated whole saliva and blood samples were collected from 161 individuals referred to colonoscopy with symptoms associated with CRC. The results of the examination, as well as previous and/or current other diseases were recorded. In a blinded study, the authors used an in-house TIMP-1 ELISA previously validated for use in saliva and plasma to determine total levels of TIMP-1.

Results: Fifty-six of the patients (35%) were diagnosed with CRC. Plasma TIMP-1 levels were significantly elevated in CRC patients compared with patients with other, non-malignant diseases and individuals without disease. Significant differences in saliva TIMP-1 levels between CRC patients and individuals without CRC could not be demonstrated. In addition, no correlation was found between levels of TIMP-1 in plasma and saliva.

Conclusion: Total levels of TIMP-1 in saliva do not reflect the presence of CRC, and TIMP-1 saliva measurements thus cannot substitute plasma TIMP-1 measurements in detection of CRC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor* / blood
  • Biomarkers, Tumor* / metabolism
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / metabolism
  • Cross-Sectional Studies
  • Early Detection of Cancer / methods*
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • ROC Curve
  • Saliva / metabolism*
  • Statistics as Topic
  • Tissue Inhibitor of Metalloproteinase-1* / blood
  • Tissue Inhibitor of Metalloproteinase-1* / metabolism

Substances

  • Biomarkers, Tumor
  • Tissue Inhibitor of Metalloproteinase-1